Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
ACTH-Secreting Pituitary Adenoma
/ genetics
Cell Line, Tumor
Cell Proliferation
Cyclins
/ biosynthesis
Gonadotropins
/ metabolism
Growth Hormone-Secreting Pituitary Adenoma
/ genetics
Humans
MicroRNAs
/ genetics
Mitogen-Activated Protein Kinases
/ genetics
Neoplasm Invasiveness
/ genetics
Oncogene Protein v-akt
/ genetics
PTEN Phosphohydrolase
/ genetics
Pituitary Neoplasms
/ genetics
STAT3 Transcription Factor
/ genetics
Signal Transduction
/ genetics
Invasiveness
MicroRNA
PTEN
Pituitary adenoma
Proliferation
miR-410-3p
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
22
12
2018
accepted:
16
04
2019
pubmed:
6
6
2019
medline:
2
6
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
miR-410-3p plays opposite roles in different cancers and may act as an oncomiR or tumor suppressor miR. The purpose of this study was to assess the role of miR-410-3p in somatotroph, gonadotroph, and corticotroph pituitary adenomas. Tissue samples were obtained from 75 patients with pituitary adenoma. miR-410-3p expression was assessed using qRT-PCR performed on RNA isolated from fresh frozen samples. In vitro experiments were performed on cell lines derived from somatotroph (GH3), gonadotroph (RC-4B/C), and corticotroph (AtT-20) pituitary tumors. Cells were transfected with synthetic mimic of miR-410-3p or non-targeting scrambled-miR control. Subsequently, proliferation assays and transwell invasion assays were performed. The expression of cyclin D1, E1, and B1 in cells after transfection was determined using qRT-PCR. The activation of MAPK, PTEN/AKT and STAT3 signaling pathways were assessed using western blot. We have found that the level of expression of miR-410-3p differs in particular types of pituitary adenomas. miR-410-3p significantly upregulates proliferation and invasiveness of RC-4B/C and AtT-20 cells, while inhibiting GH3 cells. We observed that the levels of cyclin B1 upon transfection with miR-410-3p mimic were increased in RC-4B/C and AtT-20, yet decreased in GH3 cells. We have shown that miR-410-3p promoted the activation of MAPK, PTEN/AKT, and STAT3 signaling pathways in RC-4B/C and AtT-20 cells, but suppressed their activity in GH3 cells. miR-410-3p acts as an oncomiR in gonadotroph and corticotroph adenoma cells, while as a tumor suppressor miR in somatotroph adenoma cells.
Identifiants
pubmed: 31165412
doi: 10.1007/s12020-019-01960-7
pii: 10.1007/s12020-019-01960-7
pmc: PMC6717603
doi:
Substances chimiques
Cyclins
0
Gonadotropins
0
MIRN410 microRNA, human
0
MicroRNAs
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Oncogene Protein v-akt
EC 2.7.11.1
Mitogen-Activated Protein Kinases
EC 2.7.11.24
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
646-655Subventions
Organisme : Narodowe Centrum Nauki
ID : UMO-2016/23/N/NZ5/02597
Pays : International
Organisme : Warszawski Uniwersytet Medyczny
ID : 1M15/PM1/17
Pays : International
Références
Int J Endocrinol. 2014;2014:435171
pubmed: 25548562
Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):629-639
pubmed: 27923456
Oncogene. 2011 Apr 21;30(16):1880-91
pubmed: 21170085
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Biomed Pharmacother. 2018 May;101:585-590
pubmed: 29518604
EMBO J. 1995 May 1;14(9):1878-91
pubmed: 7743995
Oncogene. 2005 Nov 14;24(50):7443-54
pubmed: 16288291
Clin Cancer Res. 2018 Nov 15;24(22):5757-5766
pubmed: 29980532
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
J Clin Endocrinol Metab. 2010 Oct;95(10):E181-91
pubmed: 20668041
Cell Cycle. 2015;14(16):2590-7
pubmed: 26125663
Cell Physiol Biochem. 2016;39(1):303-15
pubmed: 27351906
Nat Rev Endocrinol. 2011 May;7(5):257-66
pubmed: 21423242
Med Sci Monit. 2017 Mar 13;23:1277-1285
pubmed: 28288092
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
J Cell Physiol. 2007 Feb;210(2):370-7
pubmed: 17111382
Endocrine. 2017 Oct;58(1):184-189
pubmed: 28808880
Oncol Res. 2013;21(3):129-36
pubmed: 24512727
BMC Med Genet. 2017 Jul 14;18(1):72
pubmed: 28709401
Mol Cell Endocrinol. 2018 Mar 5;463:87-96
pubmed: 28445712
J Clin Endocrinol Metab. 2010 Apr;95(4):1708-16
pubmed: 20164287
Endocrine. 2018 May;60(2):308-316
pubmed: 29080043
J Clin Invest. 2015 Apr;125(4):1692-702
pubmed: 25774503
J Neurooncol. 2017 Sep;134(2):253-258
pubmed: 28577032
Endocrine. 2012 Oct;42(2):285-91
pubmed: 22552912
Pituitary. 2017 Aug;20(4):450-463
pubmed: 28432562
Endocr Pathol. 2013 Mar;24(1):11-9
pubmed: 23296986
Histol Histopathol. 2016 Aug;31(8):911-20
pubmed: 26842619
Endocrine. 2010 Aug;38(1):67-75
pubmed: 20960104
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2459-2465
pubmed: 29969630
Endocrine. 2018 Dec;62(3):663-680
pubmed: 30066286
Nat Rev Cancer. 2002 Nov;2(11):836-49
pubmed: 12415254
Cell Physiol Biochem. 2017;44(2):792-803
pubmed: 29176323
Mol Cell Biol. 2005 Jul;25(13):5725-37
pubmed: 15964826
Am J Pathol. 2011 Oct;179(4):2120-30
pubmed: 21871428
Front Endocrinol (Lausanne). 2016 Jan 11;6:188
pubmed: 26793165
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Cell Res. 2008 Feb;18(2):254-67
pubmed: 18227858
Mol Cell Endocrinol. 2017 Nov 15;456:51-61
pubmed: 28089822
Endocrine. 2013 Dec;44(3):735-43
pubmed: 23576023
Eur J Cancer. 2012 Feb;48(3):389-95
pubmed: 22119203
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Endocr Relat Cancer. 2009 Dec;16(4):1329-38
pubmed: 19620247
Mol Cell Biol. 1997 Nov;17(11):6508-16
pubmed: 9343414
J Cell Biochem. 2018 Nov;119(11):8737-8742
pubmed: 30086210
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Endocrine. 2019 Apr;64(1):147-156
pubmed: 30474823
Oncotarget. 2017 Apr 25;8(17):29269-29281
pubmed: 28418928
Curr Biol. 2000 Jan 13;10(1):47-50
pubmed: 10660304
Oncol Lett. 2018 Feb;15(2):1655-1663
pubmed: 29434861
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):389-401
pubmed: 28871006
Neuroendocrinology. 1991 Sep;54(3):267-73
pubmed: 1944812
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
pubmed: 22473468
Tumour Biol. 2016 Oct;37(10):13469-13477
pubmed: 27465551
Pituitary. 2015 Oct;18(5):710-21
pubmed: 25862551
Biochem Genet. 2016 Apr;54(2):107-19
pubmed: 26718581
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5987-5993
pubmed: 30280781
Elife. 2015 Aug 12;4:
pubmed: 26267216